Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Zoledronic acid adjuvant and vaccine containing same

A technology for zoledronic acid and vaccine, applied in the field of immunology, can solve the problems of vaccine adjuvant toxicity and side effects, high price, etc., and achieve the effects of small side effects and stable performance

Active Publication Date: 2014-05-07
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the problems of existing vaccine adjuvants such as toxic side effects and high price, the present invention provides a safe, effective and stable zoledronic acid adjuvant and a vaccine containing zoledronic acid adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Zoledronic acid adjuvant and vaccine containing same
  • Zoledronic acid adjuvant and vaccine containing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The vaccine containing zoledronic acid adjuvant provided by the present invention is as follows: in each single portion of HAV antigen (that is, the single injection dose used in animal experiments), add 10 μg of zoledronic acid injection, and then add normal saline to 200ul , and mixed according to routine, the hepatitis A vaccine containing 10 μg of zoledronic acid adjuvant and 18 EU of hepatitis A antigen was obtained.

[0019] The HAV antigen is a commercially available 18EU HAV antigen solution with an antigen titer of 512EU / ml, purchased from the Institute of Medical Biology, Chinese Academy of Medical Sciences, and the zoledronic acid is a commercially available zoledronic acid injection, purchased from Jiangsu Yangzijiang Pharmaceutical Group Co., Ltd.

[0020] Embodiment 1 gained contains the hepatitis A vaccine of zoledronic acid adjuvant, and its immune test and effect are as follows:

[0021] A. Immunity

[0022] Divide 6-8 weeks old, clean-grade female IC...

Embodiment 2

[0037] The vaccine containing zoledronic acid adjuvant provided by the present invention is as follows: in each single portion of HAV antigen (that is, the single injection dose used in animal experiments), add 20 μg of zoledronic acid injection, and then add normal saline to 200ul , after conventional mixing, a hepatitis A vaccine containing zoledronic acid adjuvant was obtained; the hepatitis A vaccine and zoledronic acid injection were the same as in Example 1.

[0038] The immunoassay of the hepatitis A vaccine containing zoledronic acid adjuvant obtained in Example 2 is the same as in Example 1, and the results are shown in Table 2.

[0039] Table 2 shows the serum anti-hepatitis A antigen IgG antibody titers of mice in each experimental group within 16 weeks of use in Example 2.

[0040] Table 2

[0041]

[0042] It can be seen from the data analysis that from the 4th week, all experimental groups except the blank group can produce anti-hepatitis A antigen IgG antibo...

Embodiment 3

[0044] The vaccine containing zoledronic acid adjuvant provided by the present invention is as follows: in each single portion of HAV antigen (that is, the single injection dose used in animal experiments), add 50 μg of zoledronic acid injection, and then add normal saline to 200ul , after conventional mixing, a hepatitis A vaccine containing zoledronic acid adjuvant was obtained; the hepatitis A vaccine and zoledronic acid injection were the same as in Example 1.

[0045] The hepatitis A vaccine containing zoledronic acid adjuvant obtained in Example 3, its immune test is the same as that of Example 1, and the results are shown in Table 3.

[0046] Table 3 shows the serum anti-hepatitis A antigen IgG antibody titers of mice in each experimental group within 16 weeks of use in Example 3.

[0047] table 3

[0048]

[0049] It can be seen from the data analysis that from the 4th week onwards, all experimental groups except the blank group could produce anti-hepatitis A antig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a zoledronic acid adjuvant and a vaccine containing the same. Each dose of the vaccine comprises 10-50mu g of zoledronic acid adjuvant. The zoledronic acid adjuvant provided by the invention is small in toxic and side effect, is safe and reliable in use in an immunizing does range, can be used for inducing specific humoral immune response of antigen, close to that of an aluminum adjuvant, is easily available in raw materials and stable in performance, and can be used as an adjuvant of multiple vaccines.

Description

technical field [0001] The invention relates to a zoledronic acid immune adjuvant and a vaccine containing the zoledronic acid adjuvant, belonging to the technical field of immunology. Background technique [0002] Adjuvants are substances that specifically or non-specifically bind to immunogenic substances to induce long-term and effective specific immune responses in the body and play an auxiliary role. Adjuvants can reduce the amount of immunogen and reduce the production cost of vaccines. Relying on the rapid development of modern biotechnology and genetic engineering in recent years, great progress has been made in the development of vaccines. Recombinant subunit vaccines, anti-idiotypic antibody vaccines, nucleic acid vaccines and synthetic peptide vaccines have been developed. Due to factors such as small molecule, weak immunogenicity, and poor targeting, it is difficult to induce an effective immune response in the body, so it is necessary to use adjuvants to enhanc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61P37/04
Inventor 王海漩李虹娟胡凝珠胡云章李彦涵李建芳
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com